In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive Netarsudil (AR-13324) Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), q.d. (AM) x 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.